Search Results < Yale Cancer Center

65 results

News
Yale Research Highlights Unmet Needs for Patients With Melanoma Who Progress or Relapse After Immunotherapy Treatment
A retrospective cohort study by Yale Cancer Center researchers of nearly 200 patients with melanoma who died after receiving treatment with immunotherapy highlights a need to improve outcomes for patients who progress or relapse after the treatment.
30 Aug 2024
News
YCC 2024 Trainee Colloquium
Trainee colloquium at YCC
16 Jul 2024
News
Yale Study Finds Potential in Predicting Immunotherapy Outcomes in Patients with Melanoma
A recent study conducted by scientists at Yale Cancer Center demonstrates that spatial gene signatures can significantly enhance the prediction of immunotherapy outcomes in patients with melanoma.
26 Jun 2024
News
Accolades, Awards & Honors
Yale Cancer Center and Smilow Cancer Hospital people who have been honored
1 Jun 2024
News
FDA Accelerates Approval of Lifileucel (AMTAGVI) for Melanoma Treatment
Harriet M. Kluger, MD, Professor of Medicine (Medical Oncology); Director, Yale SPORE in Skin Cancer, Yale Cancer Center; Director, Yale Immuno-Oncology discussing Lifileucel. On February 16, 2024, the Food and Drug Administration (FDA) granted accelerated approval to lifileucel (Amtagvi), a new type of tumor-derived autologous T cell immunotherapy, developed by Iovance Biotherapeutics, Inc.
Source: Oncology Tube
19 Feb 2024
News
Dr. Kluger on the FDA Approval of Lifileucel in Advanced Melanoma
Harriet Kluger, MD, Harvey and Kate Cushing Professor of Medicine (Oncology) and of Dermatology; director, Yale SPORE in Skin Cancer; vice chair, Translational Research, Internal Medicine; chief, Division of Skin and Kidney Cancer; associate cancer center director, Education, Training and Faculty Development; deputy section chief, Medical Oncology, Yale Cancer Center, discusses the significance of the FDA approval of the tumor infiltrating lymphocyte (TIL) therapy lifileucel (Amtagvi) for patients with advanced melanoma.
Source: OncLive
16 Feb 2024
News
Immunotherapy for Metastatic Cancer on the Rise, Even Near End of Life
Researchers learn more about when immunotherapy is most effective
4 Jan 2024
News
Rare Case of Late-recurring Merkel Cell Carcinoma
Merkel cell carcinoma is a rare, aggressive skin cancer, developing in fewer than 2,000 patients in the United States annually. The disease typically presents as a red-violet, painless bump on sun-exposed skin, and definitive treatment requires surgery to remove the cancer. Because recurrence is common, patients are routinely followed for three years after excision.
23 Oct 2023
News
Yale Scientists Identify Immune Cells Critical for Immunologic Memory for Melanoma
A new study led by Yale Cancer Center researchers at Yale School of Medicine reveals that a specific population of CD8+ T-cells marked by IL-7R play an important role in better understanding anti-tumor memory.
27 Jul 2023
News
New Funding to Support Kidney Cancer Research in Braun Lab
The laboratory of David A. Braun, MD, PhD, has received approximately $5.75M in federal awards to fund mechanisms of response and resistance to immune therapy in kidney cancer at Yale Cancer Center. Funding from the National Cancer Institute and the Department of Defense will support new projects in Dr. Braun’s lab to investigate the immune microenvironment of renal cell carcinoma (RCC) or kidney cancer.
18 Jul 2023
News
Discoveries & Impact (June 2023)
Discoveries & Impact highlights select scientific discoveries across the Department of Internal Medicine...
5 Jun 2023
News
CT researchers: Vaccine to fight cancer shows promise using same mRNA technology as COVID drug
The same technology that was used to create Moderna’s COVID-19 vaccine is being targeted on melanoma, and the treatment is having positive effects, according to researchers at the Yale Cancer Center. It’s another step in using the body’s immune system to fight diseases, using a person’s own mRNA to target cancer. The randomized Phase 2 study compares personalized mRNA vaccines given along with Keytruda, an immunotherapy drug with the generic name pembrolizumab, vs. giving Keytruda alone.
Source: The Hartford Courant
16 May 2023
News
Harriet Kluger, MD, in Recognition of Kidney Cancer Awareness Month
Harriet Kluger, MD, shares her insight into progress treating and caring for patients with kidney cancer in honor of Kidney Cancer Awareness Month, March 2023.
7 Mar 2023
News
Discoveries & Impact (February 2023)
Discoveries & Impact highlights select scientific discoveries across the Department of Internal Medicine...
15 Feb 2023
News
Yale Cancer Center Award for Teaching Excellence Presented
The Yale Cancer Center Award for Teaching Excellence was presented to Sarah Goldberg, MD, MPH, at the annual Yale Cancer Center Conclave on January 5, 2023.
10 Jan 2023
News
Dr. Harriet Kluger Named Vice Chair, Collaborative Research
Harriet Kluger, MD, Harvey and Kate Cushing Professor of Internal Medicine (Oncology) and Professor of Dermatology, has been named vice chair, Collaborative Research for the Department of Internal Medicine, effective immediately.
21 Jul 2022
News
Kluger Appointed Cushing Professor of Internal Medicine and Dermatology
Dr. Harriet Kluger, an internationally renowned expert in the study and treatment of melanoma and renal cell carcinoma (RCC), was recently appointed the Harvey and Kate Cushing Professor of Internal Medicine (Oncology) and Professor of Dermatology, effective immediately.
Source: Yale News
19 Jul 2022
News
Dr. Harriet Kluger on Oncology Tube
Dr Harriet Kluger on Oncology Tube discussing Pembrolizumab + Adoptive Cell Therapy Melanoma with T-Cell data.
Source: Oncology Tube
8 Jun 2022
News
Irina Krykbaeva, PhD, Awarded 2022 Milton C. Winternitz Prize in Pathology
Irina Krykbaeva, a recent PhD graduate in the Department of Pathology at Yale School of Medicine, is the winner of the 2022 Milton C. Winternitz Prize in Pathology. The prize is awarded annually to the student who, in the opinion of the department faculty and staff, has done outstanding work in the course.
2 Jun 2022
News
Yale Research to be presented at ASCO Annual Meeting
Yale Cancer Center and Smilow Cancer Hospital scientists and clinicians are presenting research studies at the 2022 Annual Meeting of the American Society of Clinical Oncology (ASCO) June 3-7 in Chicago, IL. This year’s scientific program will feature more than 5,000 abstracts in over 120 subcategories.
27 May 2022